ReT01 ACT

ReT01 ACT (ReT01, Re-TIL) is an autologous tumour-infiltrating lymphocyte (TIL) cell therapy from Beijing Xunsheng Biomedical Research. TILs grown from the patient's own tumour tissue by the company's activation and expansion process and infused back; the company says it is given without lymphodepletion and without IL-2 injection. Its furthest stage is phase 1, for advanced cervical cancer after failure of first-line systemic therapy and advanced solid tumours. ClinicalTrials.gov registers it in one study linked below. Phase 1 in advanced solid tumours recruiting (NCT06257680); company recruitment page says 临床 Ⅱ 期 for cervical cancer, but no phase 2 registry record was found, so phase 1 is used. Whether it works in people has not been established unless a trial below reports it.